Sanofi axes four major players from its executive committee

pharmafile | February 13, 2020 | News story | Manufacturing and Production, Medical Communications Sanofi, appointments, pharma 

Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief Executive Officer Paul Hudson, who joined the company in September last year.

The reshuffle was announced during Sanofi’s fourth-quarter earnings call. The intention is to streamline the committee’s operations and cut down on internal bureaucracy. As Hudson said, the move should help “allocate more of our central expertise into our business units and increase the accountability.”

Following the move, the committee will shrink to 10 members. Those to lose their positions include Ameet Nathwani, Chief Digital and Medical Officer, who joined Sanofi in 2016 before climbing to his current role in 2019, as well as Kathleen Tregoning, Executive Vice President, External Affairs, and Dieter Weinand, Executive Vice President of Primary Care Unit.

Also facing the axe is Dominique Carouge, Executive Vice President, Business Transformation, who has been with the company since 1991, having previous served as Deputy Chief Financial Officer.

Matt Fellows

Related Content

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content